Sharad B. Murdande

Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis

Sharad B. Murdande, Michael J. Pikal, Ravi Shanker et al. · Journal of Pharmaceutical Sciences · 2009 · 387 citations

Pharmacy, Pharmaceutics, Bioavailability +14

Solubility Advantage of Amorphous Pharmaceuticals: II. Application of Quantitative Thermodynamic Relationships for Prediction of Solubility Enhancement in Structurally Diverse Insoluble Pharmaceuticals

Sharad B. Murdande, Michael J. Pikal, Ravi Shanker et al. · Pharmaceutical Research · 2010 · 198 citations

Pharmacy, Pharmaceutical Analysis, Pharmaceutics +16

Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, John Litchfield et al. · Journal of Medicinal Chemistry · 2011 · 115 citations · Full text

Life Sciences, Biochemistry, Pharmacology +14

Solubility Advantage of Amorphous Pharmaceuticals, Part 3: Is Maximum Solubility Advantage Experimentally Attainable and Sustainable?

Sharad B. Murdande, Michael J. Pikal, Ravi Shanker et al. · Journal of Pharmaceutical Sciences · 2011 · 109 citations

Pharmacy, Pharmaceutical Analysis, Pharmaceutics +17

Development of a self-emulsifying formulation that reduces the food effect for torcetrapib

Michael E. Perlman, Sharad B. Murdande, Mike Gumkowski et al. · International Journal of Pharmaceutics · 2007 · 86 citations

Pharmacy, Food Science, Pharmaceutics +14